Pancreatic cancer is currently one of the most lethal diseases. In recent years, increasing
evidence has shown that reprogrammed metabolism may play a critical role in the …

Chemotherapy is an important part of multimodality pancreatic cancer treatment. After
curative resection, adjuvant chemotherapy can significantly improve disease free survival …

Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …

Objective: To compare the survival outcomes associated with clinical and pathological
response in pancreatic ductal adenocarcinoma (PDAC) patients receiving neoadjuvant …

Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …

Gemcitabine and nab-paclitaxel (GEM-NAB) and the combination of 5-fluorouracil,
oxaliplatin, and irinotecan (FOLFIRINOX) are valid first-line options for advanced or …

Background The systemic immune-inflammation index (SII), calculated using absolute
platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival …

Locally advanced pancreatic cancer (LAPC) has several definitions but essentially is a
nonmetastasized pancreatic cancer, in which upfront resection is considered not beneficial …

Background Large pragmatic studies of patients who received 5-fluorouracil with leucovorin,
irinotecan, and oxaliplatin ([m] FOLFIRINOX) as initial treatment for localized pancreatic …

Objective The aim of the present systematic review was to collect, analyze, and critically
evaluate the role of irreversible electroporation (IRE) in locally advanced pancreatic cancer …